Related Experiment Video

Updated: Jun 23, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

[Circumventing resistance to imatinib therapy in chronic myeloid leukemia]

Yosuke Minami1, Tomoki Naoe

  • 1Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|April 22, 2009
PubMed

Insights

Imatinib resistance in chronic myeloid leukemia is often caused by ABL-kinase domain mutations or persistent stem cells. Novel agents are being developed to overcome these challenges and improve treatment outcomes.

Area of Science:

  • Oncology
  • Hematology
  • Molecular Biology

Context:

  • Imatinib is a tyrosine kinase inhibitor used for chronic myeloid leukemia (CML).
  • Resistance to imatinib is a significant clinical challenge in CML treatment.
  • Point mutations in the ABL-kinase domain are a primary cause of imatinib resistance.

Purpose:

  • To review the mechanisms of imatinib resistance in CML.
  • To discuss the challenges posed by persistent leukemic stem cells.
  • To highlight the development of novel therapeutic agents.

Summary:

  • Resistance to imatinib in chronic myeloid leukemia (CML) is a major problem, often arising from specific mutations in the ABL-kinase domain of leukemic cells.
  • The persistence of primitive leukemic stem cell progenitors, which may be resistant to imatinib, contributes to treatment failure.
  • Various new drugs have been developed to effectively combat imatinib resistance and persistent disease.

Impact:

  • Understanding resistance mechanisms is crucial for developing effective CML therapies.
  • Novel agents offer hope for patients who are resistant to imatinib.
  • Advances in ABL-kinase inhibitor therapy are improving long-term CML management.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...